Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05849558
Other study ID # URSO - 003
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 22, 2022
Est. completion date December 31, 2023

Study information

Verified date April 2023
Source MinaPharm Pharmaceuticals
Contact Gamal Dr Esmat, PhD
Phone +202 01222455468
Email g_esmat@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients


Description:

Research Question: Compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated chronic liver diseased patients Primary Objective: To assess the efficacy of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA 250mg alone and versus Placebo in the reduction of total serum bilirubin, Direct serum bilirubin and elevated liver Enzymes from baseline to End of Treatment (EOT) Secondary Objectives: - To assess the efficacy of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo in reducing the degree of steatosis as measured by Vibration-controlled transient elastography with Controlled Attenuation Parameter (CAP) - To assess the safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo among compensated Chronic Liver Diseased Patients - To describe improvement in quality of life for patients after treatment A study population of 297 patients suffering from compensated chronic Liver Disease, who will be randomized according to Vibration-controlled transient elastography in screening visit into 2 groups: - Group 1: with non-cirrhosis, F0, F1 and F2. - Group 2: with advanced fibrosis and cirrhosis, F3 and F4. Each group will receive either Ursoplus® capsules (UDCA 250mg & Silymarin 140mg), or UDCA alone or Placebo, through Stratified random sampling. Duration for enrollment: 6 months Total duration of the study/subject will be approximately: 6 months for treatment and follow-up visits including the screening visit Subjects will be enrolled for a duration of 6 months including the screening visit - Screening visit 1 (Treatment initiation) - Visit 2: after 1st month, follow-up 1 - Visit 3: after 2nd month, follow-up 2 - Visit 4: after 3rd month, follow-up 3 - Visit 5: after 4th month, follow-up 4 - Visit 6: after 5th month, follow-up 5 - End of Study visit, after 6th month of treatment, follow-up 6


Recruitment information / eligibility

Status Recruiting
Enrollment 297
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male and female patients aged = 18 2. Subjects with Compensated Chronic Liver Disease, defined as child 5-7. 3. Patients with mild disturbance of liver biochemical profile (elevated Total Serum Bilirubin = 3 mg/dl, or elevated Direct Serum Bilirubin = 2 mg/dl, or elevated one or more of liver enzymes, up to 3 times of the normal level (Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) & Gamma Glutamyl Transpeptidase (GGT)). 4. Non-diabetic subjects and subjects with Controlled DM-type 1 and 2 patients, HbA1C up to 7.5% 5. Non-pregnant or lactating female patients 6. Subjects who are willing to sign Informed Consent Form (ICF) and ready to comply with the protocol for the duration of the study Exclusion Criteria: 1. Subjects with a history of hypersensitivity to any of the ingredients of the medications being studied 2. Subjects with positive PCR/or antibodies to Hepatitis C in the past 6 months 3. Subjects with positive hepatitis B surface antigen (HBsAg) 4. Subjects with elevated liver enzymes more than 3 times of the normal level Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) & Gamma Glutamyl Transpeptidase (GGT). 5. Subjects with Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC). 6. Subjects with Child Pugh Score more than 7. 7. Subjects with history of bleeding varices. 8. Subjects having uncontrolled Diabetes (HbA1cmore than 7.5 %) 9. Subjects with any medical condition requiring the usage of medication that may interfere with the absorption, distribution, metabolism or excretion of the study drug such as: 1. Bile acid sequestering agents such as cholestyramine and colestipol. 2. Antacids containing aluminum hydroxide. 3. Drugs affecting lipid metabolism such as estrogens, oral and hormonal contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) 10. Subjects who are receiving other liver support drugs (including drugs of the study), 1 month before study initiation. 11. Subjects with auto immune liver disease taking corticosteroid or immune suppressant 12. Pregnant or breast-feeding women 13. Use of oral contraceptives in child bearing ladies

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ursoplus
Ursoplus® capsules (UDCA 250mg & Silymarin 140mg)
UDCA 250mg
UDCA 250mg alone
Other:
Placebo
Placebo alone

Locations

Country Name City State
Egypt Air Force Specialized Hospital Cairo New Cairo

Sponsors (1)

Lead Sponsor Collaborator
MinaPharm Pharmaceuticals

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Total serum bilirubin Change in mean Total serum bilirubin from baseline (visit 1) to End of study between the 3 treatment groups Up to 6 months
Primary Change in Direct Serum Bilirubin Change in mean Direct Serum Bilirubin from baseline (visit 1) to End of study between the 3 treatment groups Up to 6 months
Primary Change in Elevated Liver Enzymes Change in mean AST & ALT from baseline (visit 1) to End of study between the 3 treatment groups Up to 6 months
Secondary Improved degree of Steatosis Change in the mean score of Controlled Attenuation Parameter (CAP) from baseline (visit 1) to End of study between the 3 treatment groups, measured by Vibration-controlled transient elastography Up to 6 months
Secondary Improved quality of life Change in the mean Score of different items of the RAND 36-Item Health Survey between the 3 treatment groups after 3 months (visit 4) and 6 months of treatment (End of study visit). Up to 6 months
Secondary Incidence of adverse events (AEs) Percent of serious (SAEs)/ non-serious adverse events (AEs), including percent changes in lab tests and percent of AEs leading to permanent discontinuation of the study drug. Up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT03704792 - Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference N/A
Terminated NCT02949375 - Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease Phase 2
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT00756171 - Colesevelam Versus Placebo in Cholestatic Pruritus Phase 2/Phase 3
Completed NCT01195181 - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Phase 4
Completed NCT05044663 - Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT04802954 - Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients N/A
Recruiting NCT04622449 - Etiopathogenesis of Anemia in Chronic Liver Disease
Enrolling by invitation NCT05836246 - The Development of Quantitative Ultrasound Imaging Software Platform
Completed NCT03087344 - Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis N/A
Completed NCT04751045 - Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies N/A
Not yet recruiting NCT04526548 - A Diagnostic Study on Patients With Drug-induced Liver Injury
Withdrawn NCT02899325 - FDGal PET/CT to Detect Hepatocellular Carcinoma
Suspended NCT02650011 - Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
Terminated NCT02530567 - Non-invasive Evaluation of Portal Pressure by MRI N/A
Completed NCT01851252 - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy Phase 1
Terminated NCT01756690 - Predicting Lung Injury From Transfusion in Patients With Liver Disease N/A
Completed NCT01600105 - Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) Phase 4
Completed NCT01008293 - Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life Phase 2/Phase 3